Literature DB >> 9300236

Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta-cell mass and function.

J F Merino1, V Nacher, M Raurell, O Aranda, J Soler, E Montanya.   

Abstract

Insulin treatment may improve the outcome of islet transplantation. To determine the effects of insulin treatment on transplanted islets, 4 groups of streptozotocin-diabetic C57BL/6 mice were transplanted with 100 islets, an insufficient beta-cell mass to restore normoglycaemia. Groups 1 (n = 12) and 2 (n = 12), were kept normoglycaemic with insulin treatment from day 10 before transplantation to day 14 after transplantation; groups 3 (n = 12) and 4 (n = 18), were not treated with insulin. Grafts were harvested 14 (groups 1 and 3) or 60 (groups 2 and 4) days after transplantation and beta-cell mass and replication were measured. When insulin was discontinued all mice maintained normoglycaemia; in contrast, non-insulin-treated groups remained hyperglycaemic throughout the study. Fourteen days after transplantation the beta-cell mass was reduced both in group 1 (0.09 +/- 0.01 mg) and group 3 (0.14 +/- 0.02 mg) compared to the initially transplanted mass (0.22 +/- 0.02 mg, p < 0.01); beta-cell replication and area did not change in group 1, but were increased in group 3. Insulin content, expressed as a function of beta-cell mass, was maintained in group 1 grafts (12.5 +/- 2.0 micrograms/mg), but was severely reduced in group 3 (1.0 +/- 0.2 micrograms/mg) compared to non-transplanted islets (20.4 +/- 3.3 micrograms/mg). In group 2, beta-cell mass increased when insulin was discontinued; 60 days after transplantation beta-cell mass was similar to the initially transplanted mass (0.23 +/- 0.04 mg), glucose levels after an intraperitoneal glucose challenge were normal, and insulin content was preserved (19.6 +/- 2.7 micrograms/mg). In contrast, beta-cell mass was progressively reduced in group 4 (0.08 +/- 0.02 mg, p < 0.001). In summary, insulin treatment reduced the beta-cell mass needed to achieve normoglycaemia in islet transplantation. Islets transplanted to insulin-treated mice showed better beta-cell function, preserved insulin content, and were able to increase their beta-cell mass to meet an increased functional demand.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300236     DOI: 10.1007/s001250050781

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  11 in total

1.  FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model.

Authors:  Taeko Uonaga; Kentaro Toyoda; Teru Okitsu; Xiaotong Zhuang; Shunsuke Yamane; Shinji Uemoto; Nobuya Inagaki
Journal:  Islets       Date:  2010 Jul-Aug       Impact factor: 2.694

2.  Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome.

Authors:  N Téllez; M Montolio; E Estil-les; J Escoriza; J Soler; E Montanya
Journal:  Diabetologia       Date:  2007-01-13       Impact factor: 10.122

3.  Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice.

Authors:  H E Levitt; T J Cyphert; J L Pascoe; D A Hollern; N Abraham; R J Lundell; T Rosa; L C Romano; B Zou; C P O'Donnell; A F Stewart; A Garcia-Ocaña; L C Alonso
Journal:  Diabetologia       Date:  2010-10-09       Impact factor: 10.122

Review 4.  Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models.

Authors:  M C Deeds; J M Anderson; A S Armstrong; D A Gastineau; H J Hiddinga; A Jahangir; N L Eberhardt; Y C Kudva
Journal:  Lab Anim       Date:  2011-04-08       Impact factor: 2.471

5.  Adaptive β-cell proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression.

Authors:  Rachel E Stamateris; Rohit B Sharma; Douglas A Hollern; Laura C Alonso
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-14       Impact factor: 4.310

6.  Factors affecting transplant outcomes in diabetic nude mice receiving human, porcine, and nonhuman primate islets: analysis of 335 transplantations.

Authors:  Gopalakrishnan Loganathan; Melanie L Graham; David M Radosevich; Sajjad M Soltani; Mukesh Tiwari; Takayuki Anazawa; Klearchos K Papas; David E R Sutherland; Bernhard J Hering; A N Balamurugan
Journal:  Transplantation       Date:  2013-06-27       Impact factor: 4.939

7.  Implanting 1.1B4 human β-cell pseudoislets improves glycaemic control in diabetic severe combined immune deficient mice.

Authors:  Alastair D Green; Srividya Vasu; Neville H McClenaghan; Peter R Flatt
Journal:  World J Diabetes       Date:  2016-11-15

8.  Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice.

Authors:  Silvia Ribback; Jenny Sonke; Andrea Lohr; Josephine Frohme; Kristin Peters; Johannes Holm; Michele Peters; Antonio Cigliano; Diego F Calvisi; Frank Dombrowski
Journal:  Oncotarget       Date:  2017-11-01

9.  Beneficial effect of insulin treatment on islet transplantation outcomes in Akita mice.

Authors:  Kazuhide Kikawa; Daisuke Sakano; Nobuaki Shiraki; Tomonori Tsuyama; Kazuhiko Kume; Fumio Endo; Shoen Kume
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  Impact of the Type of Continuous Insulin Administration on Metabolism in a Diabetic Rat Model.

Authors:  A Schaschkow; C Mura; S Dal; A Langlois; E Seyfritz; C Sookhareea; W Bietiger; C Peronet; N Jeandidier; M Pinget; S Sigrist; E Maillard
Journal:  J Diabetes Res       Date:  2016-07-18       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.